Skip navigation

Navigate Country-Specific Regulations and Reimbursement Models ● Optimise Stakeholder Collaboration ● Utilise Real World Data Collection

April 1-3, 2020
  • Barcelona, Spain

CBI’s 5th Annual Managed Access Programmes and Accelerated Pathways is dedicated to the nuances and complexities of designing and implementing Early Access Programmes. Focused on global considerations for a variety of access management programmes, including, but not limited to: Expanded Access Programmes, Early Access Programmes, Compassionate Use Programmes, Named Patient Programmes and Managed Access Programmes.

A broad array of key stakeholders will come together for in-depth and meaningful discussions on Managed Access Programmes where the implications, prevailing policies and current industry approaches are discussed in detail. Don’t miss the opportunity to join your peers and share best practices around providing investigational, pre-launch or end-of-lifecycle drugs to patients for treatment purposes.

Featuring Cutting-Edge Topics:

  • Nomenclature Clarification —
    Consensus on Universal Demand for Common Language
  • Navigate Regulation Updates in Europe —
    Latest Changes in EMA and MHRA
  • Discover Latest Legislative Changes in the US and Impact Globally — 21st Century Cures Act
  • Patient and Physician Spotlight — Hear Directly from Them
  • Programme Spotlight —
    Inside Look at Successful Managed Access Programmes
  • Industry Paradox —
    Earlier the Access, Harder the Reimbursement
  • Evaluate Country-Specific Reimbursement Models
  • Leverage Real-World Data and Data Capturing to Support the Regulatory Approval Process
  • Shine Light on Company-Specific Strategies —
    From Small Biotech to Large Commercial
  • Global Think Tank and Interactive Dialogues for
    Actionable Takeaways

Previous Attendee Acclaim:

GREAT INSIGHTS from a variety of perspectives including the patients, regulators and manufacturers, who all ADDRESSED REAL ISSUES.

Vice President, AmerisourceBergen

I learned a tremendous amount and have many NEW PERSPECTIVES to bring back to my own work. The conference gave me NEW INSIGHTS to consider related to reimbursement and real-world data generation when planning Expanded Access/Pre-Approval Access programs.

Early Patient Access Program Lead, Bristol-Myers Squibb

Very informative conference.
GREAT SPEAKERS and collaborative meeting!

Associate Director, Amicus Therapeutics

Managed Access Programmes and Accelerated Pathways

Navigate Country-Specific Regulations and Reimbursement Models ● Optimise Stakeholder Collaboration ● Utilise Real World Data Collection

CBI’s 5th Annual Managed Access Programmes and Accelerated Pathways is dedicated to the nuances and complexities of designing and implementing Early Access Programmes. Focused on global considerations for a variety of access management programmes, including, but not limited to: Expanded Access Programmes, Early Access Programmes, Compassionate Use Programmes, Named Patient Programmes and Managed Access Programmes.

A broad array of key stakeholders will come together for in-depth and meaningful discussions on Managed Access Programmes where the implications, prevailing policies and current industry approaches are discussed in detail. Don’t miss the opportunity to join your peers and share best practices around providing investigational, pre-launch or end-of-lifecycle drugs to patients for treatment purposes.

Featuring Cutting-Edge Topics:

  • Nomenclature Clarification —
    Consensus on Universal Demand for Common Language
  • Navigate Regulation Updates in Europe —
    Latest Changes in EMA and MHRA
  • Discover Latest Legislative Changes in the US and Impact Globally — 21st Century Cures Act
  • Patient and Physician Spotlight — Hear Directly from Them
  • Programme Spotlight —
    Inside Look at Successful Managed Access Programmes
  • Industry Paradox —
    Earlier the Access, Harder the Reimbursement
  • Evaluate Country-Specific Reimbursement Models
  • Leverage Real-World Data and Data Capturing to Support the Regulatory Approval Process
  • Shine Light on Company-Specific Strategies —
    From Small Biotech to Large Commercial
  • Global Think Tank and Interactive Dialogues for
    Actionable Takeaways

Previous Attendee Acclaim:

GREAT INSIGHTS from a variety of perspectives including the patients, regulators and manufacturers, who all ADDRESSED REAL ISSUES.

Vice President, AmerisourceBergen

I learned a tremendous amount and have many NEW PERSPECTIVES to bring back to my own work. The conference gave me NEW INSIGHTS to consider related to reimbursement and real-world data generation when planning Expanded Access/Pre-Approval Access programs.

Early Patient Access Program Lead, Bristol-Myers Squibb

Very informative conference.
GREAT SPEAKERS and collaborative meeting!

Associate Director, Amicus Therapeutics